Tirzepatide

What is Tirzepatide?

Tirzepatide is a once-weekly injectable medication that activates two gut-hormone receptors at the same time: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is the first medication of this 'twincretin' class, and it is sold under the brand names Mounjaro and Zepbound, both manufactured by Eli Lilly.

Unlike compounded research peptides, tirzepatide is an FDA-approved drug. Zepbound is approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and Mounjaro is approved to improve blood-sugar control in adults with type 2 diabetes. Because it is a branded, approved product, it is prescribed and dispensed through the standard pharmacy system under physician supervision.

How Tirzepatide works

Tirzepatide's defining feature is dual incretin action. The GLP-1 arm slows gastric emptying, blunts appetite through receptors in the brain, and stimulates glucose-dependent insulin release. The GIP arm adds a complementary effect on insulin secretion and, importantly, appears to further improve appetite regulation and how the body handles fat and energy.

Together these two pathways produce a stronger reduction in food intake and a larger improvement in metabolic control than GLP-1 activation alone. The net clinical effect is reduced hunger, earlier fullness, better post-meal glucose handling, and — over months — substantial loss of body weight, including visceral (belly) fat.

What Tirzepatide is used for

What the evidence shows

Tirzepatide is supported by large, high-quality human randomized controlled trials — a different tier of evidence than most peptides in this library. In the pivotal SURMOUNT-1 obesity trial, adults without diabetes lost on average roughly 15% to 21% of body weight at the higher doses over 72 weeks, versus about 3% on placebo [1].

In head-to-head diabetes research (the SURPASS program), tirzepatide produced greater reductions in HbA1c and body weight than once-weekly semaglutide [2], and the SURMOUNT-2 trial confirmed clinically significant weight loss in people who also have type 2 diabetes [3].

This is what separates tirzepatide from experimental compounds: its benefits and its risks are established in tens of thousands of patient-years of controlled data, which is why it carries FDA approval and a defined label rather than 'preclinical promise.'

Dosing & administration context

Tirzepatide is given as a once-weekly subcutaneous injection. Treatment starts at a low dose and is titrated upward over months, which allows the body to adjust and limits gastrointestinal side effects. The approved products come as prefilled pens or vials at fixed strengths.

The specific starting dose, titration schedule, and target dose are set by the prescribing physician based on your goals, tolerance, and whether the indication is weight management or diabetes. We frame this as clinical context, not a self-dosing guide — dose escalation is individualized and monitored, and product sourced outside the licensed pharmacy system carries no guarantee of identity, purity, or sterility.

Tirzepatide is an FDA-approved medication (Zepbound for weight management, Mounjaro for type 2 diabetes). Content on this page is educational context for physician-supervised treatment — not a dosing guide or a substitute for medical advice.

Safety & side effects

The most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — and are usually mild to moderate, most noticeable during dose increases, and tend to ease with time and slow titration. Because tirzepatide is FDA-approved, its adverse-effect profile is well characterized from large trials.

It carries a boxed warning regarding thyroid C-cell tumors seen in rodents, so it is not used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Rarer but important risks include pancreatitis, gallbladder disease, and, in people on insulin or sulfonylureas, low blood sugar. We screen for these before prescribing and monitor throughout treatment.

How Strong Health prescribes Tirzepatide

At Strong Health, tirzepatide is prescribed only after a physician evaluation that reviews your medical history, weight and metabolic goals, medications, and relevant labs. Because it is an FDA-approved medication, we prioritize dispensing the branded product (Mounjaro or Zepbound) through licensed pharmacies whenever it is available.

Availability of the branded pens has been affected by periodic shortages, and access to any compounded alternative is state-dependent and tied to FDA shortage status — so what we can offer is determined by current regulations and supply, not by preference. Your physician sets the titration schedule, monitors tolerance and metabolic markers at scheduled reviews, and adjusts or stops treatment based on your response and safety.

Available in person at our Miami (Brickell) clinic and via telehealth across our service areas.

Frequently asked questions